SCHEDULE: Spruce Biosciences: Major Stake Acquired by AIGH Capital

AIGH Capital Management and affiliated entities now beneficially own 9.1% of Spruce Biosciences' common stock, as disclosed in a Schedule 13G filing.

Summary

• AIGH Capital Management, LLC, along with AIGH Investment Partners, L.L.C. and Mr. Orin Hirschman, have jointly filed a Schedule 13G.
• This filing indicates beneficial ownership of 250,000 shares of Spruce Biosciences, Inc. common stock.
• This ownership represents 9.1% of the class of securities.
• The reporting persons have sole voting power and sole dispositive power over these shares.
• The filing is made as of June 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it reports on an existing investment and ownership stake rather than new company performance or strategic changes.

Positives

• Significant investment by AIGH Capital Management, indicating confidence in Spruce Biosciences.
• AIGH Capital Management holds 9.1% of the outstanding common stock, demonstrating substantial backing.
• The reporting persons have full control over voting and disposition of their shares.

Risks

• Potential for increased market influence or activism from a significant shareholder like AIGH Capital.
• Concentration of ownership could lead to specific shareholder demands impacting company strategy.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Spruce Biosciences. It solely reports on the ownership stake of AIGH Capital Management.

Management Comments

• Mr. Orin Hirschman certifies that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that significant stake acquisitions, as reported in Schedule 13G filings, often signal increased investor interest or a shift in institutional ownership within the biotechnology sector, which is characterized by high R&D investment and potential for significant market shifts.

Stakeholder Impact

• Shareholders may see increased institutional interest in Spruce Biosciences due to AIGH Capital's significant stake.
• The company's management may face increased scrutiny or engagement from AIGH Capital as a major shareholder.

Key Dates

Keywords

Spruce Biosciences, AIGH Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Shareholder